Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974855 · ClinicalTrials.gov registry record · Phase 2
PF-06741086 Multiple Dose Study in Severe Hemophilia
A Phase 2 study of Hemophilia A or B, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 10
- Study locations
NCT02974855: Completed Phase 2 study of Hemophilia A or B, sponsored by Pfizer.
NCT02974855 is a Phase 2 study of Hemophilia A or B that has completed, run by Pfizer. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974855, a Phase 2 study of Hemophilia A or B, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth def
Conditions Studied
Interventions
- BIOLOGICAL PF-06741086
Study Locations (10)
Other
- Hospital Dr. Sotero del Rio - Santiago
- Klinicki bolnicki centar Zagreb - Zagreb
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne - Gdansk
- UniversitatsSpital Zurich, Klinik fur Hamatologie - Zurich
Colorado
- UC Denver Hemophilia and Thrombosis Center - Pharmacy - Aurora
- UC Denver Hemophilia and Thrombosis Center - Aurora
Illinois
- Pharmacy - Chicago
- Rush University Medical Center - Chicago
Eastern Cape
- Phoenix Pharma (Pty) Ltd - Port Elizabeth
Gauteng
- Haemophilia Comprehensive Care Centre - Johannesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 2 |
What the finished NCT02974855 record still lists
NCT02974855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Hemophilia A or B appearing as the primary indexed condition, and to 1 intervention - of which PF-06741086 is the first listed.
NCT02974855 lists 10 locations in 5 states (Other, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT02974855 about?
NCT02974855 is a clinical study titled "PF-06741086 Multiple Dose Study in Severe Hemophilia". This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
What is the current status of trial NCT02974855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2017-03-08. Estimated completion is 2018-12-03.
What conditions does trial NCT02974855 study?
This clinical trial studies the following conditions: Hemophilia A or B.
What interventions are being tested in trial NCT02974855?
The interventions under investigation include: PF-06741086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02974855?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02974855 being conducted?
This trial has 10 study locations across Colorado, Illinois, Eastern Cape, Gauteng. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974855's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI